

Perspective

For numerous tablets already on the market, population-based studies fail to exhibit patient-relevant benefits. In fact, the ten highest-grossing tablets in the USA fail to enhance the prerequisites for most patients, leading to high numbers needed to treat (NNT). In high-risk patients, the NNTs are smaller, however the hassle persists. Thus, a move from chronically treating symptoms towards a more precise and ideally curative therapy, effective for almost every patient, is of utmost importance.

Since the 1950s, we have discovered a consistent decline in our efficacy to translate biomedical research into successful drug